- About Us
-
Our Business
-
- Therapeutic Areas Our portfolio is diverse and based upon - Market Research, Regulatory & IP.
- Licensing Licensing activities are excellent opportunities for companies to expand their portfolio.
- Biosimilar Biosimilar are biologic medicines that are developed to match their reference medicine.
-
- CRAM India has grown to be one of the key nations complying GMP manufacturing norms.
- Medical Devices REVA help our clients to deliver customized, cost-effective medical device value chain.
-
API
-
Dosage form
-
-
Operations
- At Reva, we have requisite infrastructure, with a balanced reach across Regulated, Emerging & Expansion markets. And we are committed to helping create healthier communities worldwide through education, outreach and better access to treatment.
-
Research & Development
-
Manufacturing
-
Quality
- Media
- Contact us
Latest News
This week, Phispers has news from Canada, where its drug lobby group has urged the government to take bold steps like...
Read More
Read More
The US Food and Drug Administration (FDA) released its GDUFA II user fees for fiscal 2020. Unlike the previous year,...
Read More
Read More
NEW DELHI, July 30, 2019 /PRNewswire/ -- Speaking of the merger of Pfizer's out of patent business (Upjohn) and Mylan...
Read More
Read More
Japanese firms have generally cracked the code of working in India's huge domestic market, but the extent of success...
Read More
Read More
NASSCOM, the apex trade association of companies that offer information technology (IT) services from India, is getting...
Read More
Read More
Retail investors prefer to invest in stocks, sectors and themes whose recent performance tends be good and avoid those...
Read More
Read More
HÀNOI — The European Chamber of Commerce in Viet Nam (Eurocham) highly values the potential of Viet Nam to become a...
Read More
Read More
Sun Pharma on Monday announced the launch of Ezallor Sprinkle capsules, used for treatment of elevated lipid disorders...
Read More
Read More
The U.S. Food and Drug Administration (FDA) has raised doubts about Strides Pharma Sciences Ltd's quality-control...
Read More
Read More
Indian pharma players were pulled up fewer times by the US Food and Drug Administration (USFDA) in 2018 than in the past...
Read More
Read More
Glenmark Pharmaceuticals and Torrent Pharmaceuticals on Thursday said they have entered into a licensing agreement to...
Read More
Read More
The Trump administration has abandoned a centerpiece of its efforts to address high drug prices, backing away from...
Read More
Read More